Page 114 - GTM-2-3

Global Translational Medicine TEs link to Parkinson’s risk and progression

References pleomorphic pathology. Neuron, 44: 601–607.

1. Emamzadeh FN, Surguchov A, 2018, Parkinson’s disease: https://doi.org/10.1016/j.neuron.2004.11.005
Biomarkers, treatment, and risk factors. Front Neurosci, 12: 612. 14. Fernandez-Santiago R, Sharma M, 2022, What have we
https://doi.org/10.3389/fnins.2018.00612 learned from genome-wide association studies (GWAS) in
Parkinson’s disease? Ageing Res Rev, 79: 101648.
2. de Lau LM, Breteler MMB, 2006, Epidemiology of
Parkinson’s disease. Lancet Neurol, 5: 525–535. https://doi.org/10.1016/j.arr.2022.101648
https://doi.org/10.1016/S1474-4422(06)70471-9 15. Nalls MA, Blauwendraat C, Vallerga CL, et al., 2019,
Identification of novel risk loci, causal insights, and heritable
3. GBD 2016 Neurology Collaborators, 2019, Global, regional, risk for Parkinson’s disease: A meta-analysis of genome-
and national burden of neurological disorders, 1990-2016: wide association studies. Lancet Neurol, 18: 1091–1102.
A systematic analysis for the Global Burden of Disease Study
2016. Lancet Neurol, 18: 459–480. https://doi.org/10.1016/S1474-4422(19)30320-5
https://doi.org/10.1016/S1474-4422(18)30499-X 16. Bustos BI, Billingsley K, Blauwendraat C, et al., 2023,
Genome-wide contribution of common short-tandem
4. Dorsey ER, Bloem BR, 2018, The Parkinson pandemic-a call
to action. JAMA Neurol, 75: 9–10. repeats to Parkinson’s disease genetic risk. Brain, 146: 65–74.
https://doi.org/10.1093/brain/awac301
https://doi.org/10.1001/jamaneurol.2017.3299
17. Le Guen Y, Napolioni V, Belloy ME, et al., 2021, Common
5. Armstrong MJ, Okun MS, 2020, Diagnosis and treatment of
Parkinson disease: A review. JAMA, 323: 548–560. X-chromosome variants are associated with Parkinson
disease risk. Ann Neurol, 90: 22–34.
https://doi.org/10.1001/jama.2019.22360
https://doi.org/10.1002/ana.26051
6. Schapira AHV, Chaudhuri KR, Jenner P, 2017, Non-motor
features of Parkinson disease. Nat Rev Neurosci, 18: 435–450. 18. Burns KH, Boeke JD, 2012, Human transposon tectonics.
Cell, 149: 740–752.
https://doi.org/10.1038/nrn.2017.62
https://doi.org/10.1016/j.cell.2012.04.019
7. Dickson DW, Braak H, Duda JE, et al., 2009,
Neuropathological assessment of Parkinson’s disease: 19. Nurk S, Koren S, Rhie A, et al., 2022, The complete sequence
Refining the diagnostic criteria. Lancet Neurol, 8: 1150–1157. of a human genome. Science, 376: 44–53.
https://doi.org/10.1016/S1474-4422(09)70238-8 https://doi.org/10.1126/science.abj6987
8. Obeso JA, Stamelou M, Goetz CG, et al., 2017, Past, 20. Bourque G, Burns KH, Gehring M, et al., 2018, Ten things
present, and future of Parkinson’s disease: A special essay you should know about transposable elements. Genome Biol,
on the 200 Anniversary of the Shaking Palsy. Mov Disord, 19: 199.
th
32: 1264–1310. https://doi.org/10.1186/s13059-018-1577-z
https://doi.org/10.1002/mds.27115 21. Finnegan DJ, 1989, Eukaryotic transposable elements and
9. Poewe W, Seppi K, Tanner CM, et al., 2017, Parkinson genome evolution. Trends Genet, 5: 103–107.
disease. Nat Rev Dis Primers, 3: 17013. https://doi.org/10.1016/0168-9525(89)90039-5
https://doi.org/10.1038/nrdp.2017.13 22. Wicker T, Sabot F, Hua-Van A, et al., 2007, A unified
10. Deng H, Wang P, Jankovic J, 2018, The genetics of Parkinson classification system for eukaryotic transposable elements.
disease. Ageing Res Rev, 42: 72–85. Nat Rev Genet, 8: 973–982.
https://doi.org/10.1016/j.arr.2017.12.007 https://doi.org/10.1038/nrg2165
11. Polymeropoulos MH, Lavedan C, Leroy E, et al., 1997, 23. Wells JN, Feschotte C, 2020, A field guide to eukaryotic
Mutation in the alpha-synuclein gene identified in families transposable elements. Annu Rev Genet, 54: 539–561.
with Parkinson’s disease. Science, 276: 2045–2047. https://doi.org/10.1146/annurev-genet-040620-022145
https://doi.org/10.1126/science.276.5321.2045 24. Chuong EB, Elde NC, Feschotte C, 2017, Regulatory activities
12. Kitada T, Asakawa S, Hattori N, et al., 1998, Mutations of transposable elements: From conflicts to benefits. Nat Rev
in the parkin gene cause autosomal recessive juvenile Genet, 18: 71–86.
parkinsonism. Nature, 392: 605–608. https://doi.org/10.1038/nrg.2016.139
https://doi.org/10.1038/33416 25. Hoyt SJ, Storer JM, Hartley GA, et al., 2022, From telomere
13. Zimprich A, Biskup S, Leitner P, et al., 2004, Mutations in to telomere: The transcriptional and epigenetic state of
LRRK2 cause autosomal-dominant parkinsonism with human repeat elements. Science, 376: eabk3112.

Volume 2 Issue 3 (2023) 10 https://doi.org/10.36922/gtm.1583